Interpreting the EHR-derived Glucosamine Signal in Alzheimer's disease: A Comment on Hawkinson et al. (2026)

In "Hyperglycosylation is a metabolic driver of Alzheimer’s disease" (DOI: 10.1038/s42255-026-01538-4, PMID: 42265388), Hawkinson et al. provide experimental evidence that D-glucosamine (GlcN)-mediated hyperglycosylation may contribute to Alzheimer’s disease (AD) pathology in 5xFAD mice. They further report that GlcN use documented in electronic health records is associated with higher mortality among people with AD and related dementias and faster progression from mild cognitive impairment to dementia. These findings raise an important clinical safety question, but the reported associations are insufficient to support a causal interpretation. Limited confounder adjustment and reliance on clinical documentation leave the estimates vulnerable to confounding by indication and measurement error. A subsequent analysis of data from the National Alzheimer’s Coordinating Center observed similar patterns for other supplements. The available human evidence therefore does not establish GlcN as a driver of AD progression.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-20
DOI
https://doi.org/10.5281/zenodo.24352071
Primary Topic
Alzheimer's disease research and treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Interpreting the EHR-derived Glucosamine Signal in Alzheimer's disease: A Comment on Hawkinson et al. (2026)

Elisa Araldi, Riccardo Perrone, P. Borchert, Michael Ristow et al.
1 links
Zenodo (CERN European Organization for Nuclear Research)
Alzheimer's disease research and treatments
preprint

Interpreting the EHR-derived Glucosamine Signal in Alzheimer's disease: A Comment on Hawkinson et al. (2026)

Elisa Araldi, Riccardo Perrone, P. Borchert, Michael Ristow, Roberto Pili
preprint en

Abstract

In "Hyperglycosylation is a metabolic driver of Alzheimer’s disease" (DOI: 10.1038/s42255-026-01538-4, PMID: 42265388), Hawkinson et al. provide experimental evidence that D-glucosamine (GlcN)-mediated hyperglycosylation may contribute to Alzheimer’s disease (AD) pathology in 5xFAD mice. They further report that GlcN use documented in electronic health records is associated with higher mortality among people with AD and related dementias and faster progression from mild cognitive impairment to dementia. These findings raise an important clinical safety question, but the reported associations are insufficient to support a causal interpretation. Limited confounder adjustment and reliance on clinical documentation leave the estimates vulnerable to confounding by indication and measurement error. A subsequent analysis of data from the National Alzheimer’s Coordinating Center observed similar patterns for other supplements. The available human evidence therefore does not establish GlcN as a driver of AD progression.

Zenodo (CERN European Organization for Nuclear Research)
University of Parma (IT), Joslin Diabetes Center (US), Harvard University (US), ETH Zurich (CH), University Medical Center of the Johannes Gutenberg University Mainz (DE), Charité - Universitätsmedizin Berlin (DE)
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Interpreting the EHR-derived Glucosamine Signal in Alzheimer's disease: A Comment on Hawkinson et al. (2026) — Elisa Araldi, Riccardo Perrone, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS